Menu Back toSession-9-ICH-Guidances-from-a-Global-and-Regional-Perspective

Biostatistics Industry and Regulator Forum


Session 9: ICH Guidances from a Global and Regional Perspective

    Session Chair(s)
      Aloka  Chakravarty, PhD

      Aloka Chakravarty, PhD

      • Acting Deputy Director, Office of Biostatistics, OTS, CDER
      • FDA, United States
      William  Wang, PhD

      William Wang, PhD

      • Executive Director, Clinical Safety Statistics, BARDS
      • Merck Research Laboratories, United States

    This session will examine a few ICH regulatory guidances, looking at them both from global and regional perspectives. These guidances may include the recently published ICH E9 R1 step 2b draft, the soon-to-be-published ICH E17, and the upcoming ICH E6/E8 renovation.

    In this session, we will prepare a case-study scenario for the panelists, then we will let panelists develop their own estimands in advance, which they have to present briefly and subsequently defend during the panel discussion. We will further introduce additional complexities by different intrinsic/extrinsic factors and critical quality factors across region. This will lead to the discussion of E9 R1, E17, and E6/E8 in an implementation setting.

    The panel discussion will be mixed with short presentations on the relevant ICH guidance and its regional implementation.

Contact us

Registration Questions?

Send Email
+1.215.442.6100


Call for Abstracts

Guidelines | Submit

Submission Deadline: February 12